Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab - Concepedia

Concepedia

Publication | Closed Access

Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab

70

Citations

38

References

2015

Year

Stefania Napolitano, Giulia Martini, Barbara Rinaldi, Erika Martinelli, Maria Donniacuo, Liberato Berrino, Donata Vitagliano, Floriana Morgillo, Giusi Barra, Raffaele De Palma,

Clinical Cancer Research

Abstract

The combined treatment with cetuximab and regorafenib could be a strategy to overcome resistance to anti-EGFR therapies in metastatic colorectal cancer patients.

References

	Year	Citations

Page 1